Colowick Alan
SEC-identified person · CIK 1316163 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Alumis INC. NASDAQ | Director | filed 2024 - 2025 |
| Maze Therapeutics, Inc. MAZE | Director | filed 2025 - 2025 |
| Personalis, Inc. PSNL | Director | filed 2019 - 2023 |
| Acelyrin, Inc. SLRN | Director | filed 2023 - 2023 |
| Harpoon Therapeutics, Inc. HARP | Director | filed 2021 - 2023 |
| Principia Biopharma Inc. PRNB | Director | filed 2018 - 2020 |
| Dimension Therapeutics, Inc. DMTX | Director | filed 2015 - 2017 |
| Achaogen, Inc. AKAO | Director | filed 2015 - 2017 |
| Geron Corp GERN | President, Oncology | filed 2006 - 2008 |
| Threshold Pharmaceuticals INC THLDD | Chief Medical Officer | filed 2006 - 2006 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.